

# **Summary of Studies Supporting USDA Product Licensure**

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	4X49.21
True Name	Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3- Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Pyramid 5 +PRESPONSE SQ - No distributor specified Pyramid FP 5 + Presponse SQ - Boehringer Ingelheim (Canada) Ltd.
Date of Compilation Summary	April 08, 2019

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

124 4X49.21 Page 1 of 16

Study Type	Efficacy
Pertaining to	Bovine Virus Diarrhea (BVD)
Study Purpose	Demonstration of efficacy against BVD Type 1 clinical disease,
	leukopenia, and viremia
<b>Product Administration</b>	
Study Animals	Bovine
<b>Challenge Description</b>	BVD1b NY-1 strain
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	June 14, 1994

124 4X49.21 Page 2 of 16

Study Type	Efficacy						
Pertaining to	Bovine Virus Diarrhea (BVD)						
Study Purpose	Demonstration of efficacy against persistent infection of calves						
	with BVD Type 1						
<b>Product Administration</b>	Pregnant heifers or cows prior to breeding						
Study Animals	Bovine						
Challenge Description	BVD1b 97B1415 strain						
Interval observed after							
challenge							
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.						
<b>USDA Approval Date</b>	December 10, 2003						

124 4X49.21 Page 3 of 16

Study Type	Efficacy									
Pertaining to	Bovine Virus Diar	rhea (BVD)								
Study Purpose	Demonstration of	efficacy against	BVD Type 1 (re	espiratory						
	disease) 217 days	disease) 217 days after vaccination								
<b>Product Administration</b>	One dose, subcuta	One dose, subcutaneously								
Study Animals	46 bovine calves (	23 vaccinates ar	nd 23 controls), 2	25 to 37 days						
	of age	· · · · · · · · · · · · · · · · · · ·								
<b>Challenge Description</b>	Challenged with B	SVD Type 1b, Is	olate CA040118	6A, 217 days						
	(7 months) after vaccination									
Interval observed after	Calves were obser	ved and blood v	vas collected for	14 days after						
challenge	challenge to evalu	challenge to evaluate viremia and leukopenia.								
Results	Results of the study are summarized as follows:									
	Blood was evaluated for viremia (the presence of virus) and leukopenia (at least one white blood cell count below 60% of pre-challenge baseline).  Positive for Viremia and Leukopenia:									
		Viremia	Leukopenia							
	Vaccinates	0/23 (0%)	6/23 (26%)							
	Controls	22/23 (96%)	21/23 (91%)							
	See tables on the following pages for data.									
<b>USDA Approval Date</b>	July 14, 2014			_						

124 4X49.21 Page 4 of 16

# Viremia in Vaccinates (23 bovine)

Animal						Da	ys Po	ost-C	Chall	enge					Overall
ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
21	-	-	-	-	-	-	-	-	-	-	-	ı	-	-	-
32	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-
34	-	ı	ı	-	-	-	-	ı	-	-	-	ı	-	-	-
37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
49	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
51	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
61	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
64	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
67	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
86	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
87	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
94	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
102	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
104	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
108	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

<sup>+ =</sup> positive for virus (highlighted yellow)

124 4X49.21 Page 5 of 16

<sup>- =</sup> negative for virus

# Viremia in Controls (23 bovine)

Animal						Da	ys Po	st-C	halle	nge					Overall
ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
31	-	-	-	-	-	+	+	-	+	-	-	-	-	-	+
33	-	-	-	-	-	+	-	-	-	ı	1	-	-	-	+
36	-	+	+	+	-	+	-	-	-	-	-	-	-	-	+
38	-	-	-	+	+	+	+	-	+	-	-	-	-	-	+
44	-	-	-	+	+	+	-	-	-	-	-	-	-	-	+
47	-	-	-	+	+	-	-	-	-	-	-	-	-	-	+
50	-	-	-	-	-	+	+	-	-	-	-	-	-	-	+
53	-	-	-	-	+	+	+	+	+	-	-	-	-	-	+
56	-	-	-	+	+	+	+	-	-	-	-	-	-	-	+
58	-	-	-	+	+	+	+	-	-	-	-	-	-	-	+
59	-	-	-	+	+	+	+	+	+	-	-	-	-	-	+
62	-	-	-	-	+	-	+	-	-	-	-	-	-	-	+
66	-	-	-	-	+	+	-	+	-	-	-	-	-	-	+
69	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+
70	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+
74	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
85	-	-	-	-	+	+	-	-	-	-	-	-	-	-	+
89	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+
92	-	-	-	-	-	+	+	-	-	-	-	-	-	-	+
98	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+
101	-	-	-	-	-	+	+	+	-	-	-	-	-	-	+
106	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+
107	-	-	-	-	+	+	+	-	-	-	-	-	-	-	+

<sup>+ =</sup> positive for virus (highlighted yellow)

124 4X49.21 Page 6 of 16

<sup>- =</sup> negative for virus

# Leukopenia in Vaccinates (23 bovine)

				WI	nite Blo	od Ce	ll Coun	t per e	ach Da	y Post	-Challe	enge				Overall
ID	Base -line	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
21	13.5	10.4	11.3	11.6	11.9	11.3	12.4	12.2	11.6	12.4	9.6	9.6	9.3	9.7	10.4	-
32	8.4	8.1	7.8	7.9	NA	9.9	8.9	9.7	8.9	7.1	6.6	8	8.4	10.7	12	-
34	8.9	8.7	9	9.3	9.5	8.5	8.9	9	8.6	8	8.2	4.7	5.1	6.9	8.6	+
37	13.9	12.4	12.7	12.6	11.9	11.6	11	11.4	9.4	9.3	9	9.9	10.1	10.1	9.9	-
41	8.1	8.3	7.8	9.1	8.3	7.5	7.3	7.4	7.5	5.4	5.3	5.1	6.2	7.8	8.1	-
43	8.0	7.7	8	8.8	8.1	8.6	8	8.9	7.8	8.2	6	6.9	8.1	7.4	6.8	-
48	6.2	6.6	6.8	7	6.7	6.5	6.5	6.8	7.2	3.1	3.8	5	5.6	5.8	6.1	+
49	11.1	10.6	10.9	11.1	11.8	10.5	9.4	10.1	10.4	10.5	8	8.8	8.6	10.9	11.9	-
51	8.0	8.5	9.4	10.8	10.4	11.3	9.7	10.1	10.3	8.7	5.5	6.7	7.4	7.5	8.2	-
57	8.5	9.4	9.6	9.1	9.7	8.8	9.4	9.1	9	8.8	8.4	7	8	7.5	7.3	-
61	7	7	6.8	7.9	4.6	3.9	4.5	6.6	7	6.8	6.3	8.2	8.8	8	7.9	+
64	8.1	6.6	6.1	6.6	7.2	6.2	6.9	7.2	7.1	7.4	7.1	6.8	7.8	9.5	9	-
67	6.2	5.8	5.9	6.6	6.7	6.3	3.5	4.7	5	5.1	5.4	6.4	6.4	8.2	6.1	+
68	7.6	8.2	8.5	8.7	8.7	7	5.1	5.6	6.3	6.6	7.2	7.9	8.1	9.3	9.4	-
73	8.0	8	7.9	8	8.1	7.8	7.7	6.1	5.7	5.8	5.9	6.1	7.3	7.4	9.2	-
82	11.6	11.1	11.2	17.2	12.1	11.6	11.6	11	11.5	11.4	5.7	8.1	9.6	11.5	10.8	+
86	6.6	7.2	7.1	6.8	6.8	5.9	6.3	6.1	5.8	6.7	4.2	4.6	5.9	5.9	7.2	-
87	9.2	9.4	9.9	10	7.4	8.3	7.5	10.4	8.8	8.6	9.7	9.1	8.9	9.1	9.6	-
94	11.6	11.2	11.4	10.6	10.1	9.3	9.3	9.4	9.9	10.2	8.3	8.6	9.4	11.4	11.8	-
97	6.4	6.8	7	8.1	8.3	7.7	7.4	7.9	8.3	7.5	4.8	5.3	5.7	6.6	5.8	-
102	8.7	8.3	8.8	8.7	8.9	8.2	8.2	8.5	8	6	3.8	5.5	6.3	7.1	8.1	+
104	8.3	8.4	8.6	9.2	8.9	7.9	8.1	8.9	8.5	6.9	5.3	6.7	6.7	9.9	7.9	-
108	8.1	8.1	9	7.7	8.4	11.4	7.8	9.3	11.9	10.3	10.3	8	12.7	10.6	10.2	-

#### **White Blood Cell Count:**

- Baseline is the average white blood cell (WBC) counts from 3 consecutive days, prior to challenge
- Numerical values = white blood cell count in K/μL
- Highlighted yellow = positive for leukopenia, meaning a 40% or more reduction in the total WBC count compared to baseline on that day
- NA = not applicable / no measurement on that day

# **Overall Result:**

- + = positive for leukopenia at least one day (highlighted yellow)
- = negative for leukopenia on every day

124 4X49.21 Page 7 of 16

# Leukopenia in Controls (23 bovine)

				WI	nite Blo	od Ce	ll Cour	t per e	ach Da	y Post	-Challe	enge				Overall
ID	Base -line	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Result
31	7.8	7.7	7.3	3.8	NA	4.5	3.7	3.9	6.1	10.6	7	5.9	5.5	5.9	3.2	+
33	11.3	10.5	11.9	6.5	7	7.3	5.7	6	10.3	7.9	6.8	7	7.4	8.1	7.7	+
36	8.9	9.2	8.8	5.1	6.4	5.7	5.3	5.2	6.6	7.5	6.3	5.7	5.9	5.9	6	+
38	6.5	5.9	7	4.6	4.6	3.9	3.6	3.4	7	7.3	6.1	5.4	5.3	5.6	5	+
44	10.3	10.2	10	4.1	6.2	5.8	4.3	7.3	12.7	8	5.4	5.7	6.3	5.5	5.5	+
47	7.9	8.1	7.6	4.8	5.9	5.8	4.5	5.3	7.9	6.5	6.2	5.8	5.6	5.6	6	+
50	8.2	8.9	8.9	5.9	4.6	6	5.1	6.3	10.4	8.9	6.3	5.1	5.1	5.7	5.6	+
53	7.5	8.3	8.5	3.9	4.5	4.3	3.1	3.4	3.6	7.5	6.1	4.4	5.6	5.8	5.5	+
56	9.8	7.6	9.1	3.9	6	4.5	4.4	5.3	12.2	9.8	5.4	5.2	6	5.5	6.3	+
58	8.3	8.7	9.8	5.7	6.3	7.1	5.1	5.2	8.2	8.4	6.1	6.4	7.4	6.2	6.5	-
59	10.1	11.1	12.2	8.5	7.3	8.7	7.6	7.8	9.4	12.7	13	9.9	9.5	9.9	21.6	-
62	9.5	10.2	9.8	4.9	5.5	5.1	4.2	3.9	7.5	10.7	8.6	7	6.1	6.2	5.5	+
66	6.7	8.5	8	4.5	6	5.2	4.5	5.8	7	5.8	4.8	4.6	5.1	5.4	3.9	+
69	11.1	12.1	11.4	5.1	8.1	8.8	7.2	9.4	11.3	10.5	7.8	7.4	7.1	7.4	7.7	+
70	10.7	10.1	9	4.4	6	5.8	4.4	4.5	7.5	10.8	8.5	7.4	5.6	6.4	5.8	+
74	5.8	6.2	6.4	4.2	4.7	4.2	3.3	3	4	7	5.2	4.4	4.6	4.1	4.5	+
85	8.6	8	7.8	5.7	6.8	5.4	4.5	4.3	5	6.1	6.3	7.4	7.2	7.6	7.4	+
89	8.9	8.4	8.5	3.9	5.8	6.1	4.6	4.1	9.1	8.6	5.7	4.7	5.2	5.1	5.7	+
92	7.8	7.4	5.9	4.4	4.6	3.8	3.2	3.6	4.1	4.6	3.6	3.8	3.8	4.5	4.4	+
98	7.9	7.4	8	4.5	5.9	4.2	4.1	4.1	6.5	7.3	6.5	5.8	6.1	5.9	5.8	+
101	9.9	9.3	10.5	8.5	7.6	7.2	5.6	5.5	5.3	13.4	9.6	7.2	6.5	7	5.4	+
106	7.1	7.2	7.3	4.4	5.3	4.6	3.7	5.2	7.6	5.3	5.1	6.4	5.6	6.3	6.9	+
107	10.7	10.5	10.1	6.7	7.9	7	5.5	5.7	7.8	8.9	8.7	7.5	7.1	7.6	8.8	+

#### **White Blood Cell Count:**

- Baseline is the average white blood cell (WBC) counts from 3 consecutive days, prior to challenge
- Numerical values = white blood cell count in K/μL
- Highlighted yellow = positive for leukopenia, meaning a 40% or more reduction in the total WBC count compared to baseline on that day
- NA = not applicable / no measurement on that day

# **Overall Result:**

- + = positive for leukopenia at least one day (highlighted yellow)
- = negative for leukopenia on every day

124 4X49.21 Page 8 of 16

Study Type	Efficacy
Pertaining to	Bovine Virus Diarrhea (BVD)
Study Purpose	Demonstration of efficacy against persistent infection of calves
	with BVD Type 2
<b>Product Administration</b>	Pregnant heifers or cows prior to breeding
Study Animals	Bovine
<b>Challenge Description</b>	BVD2a 96B2222 strain
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	December 10, 2003

124 4X49.21 Page 9 of 16

Study Type	Efficacy
Pertaining to	Bovine Virus Diarrhea (BVD)
Study Purpose	Demonstration of efficacy against BVD Type 2clinical disease,
	leukopenia, and viremia
<b>Product Administration</b>	
Study Animals	Bovine
<b>Challenge Description</b>	BVD2a IAF 103, BT-4A-2 strain
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	August 4, 2003

124 4X49.21 Page 10 of 16

Study Type	Efficacy
Pertaining to	Infectious Bovine Rhinotracheitis (IBR)
Study Purpose	Demonstration of efficacy against IBR (respiratory disease)
<b>Product Administration</b>	
Study Animals	Bovine
<b>Challenge Description</b>	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	September 9, 1994

124 4X49.21 Page 11 of 16

Study Type	Efficacy
Pertaining to	Mannheimia haemolytica
Study Purpose	Demonstration of efficacy against Mannheimia haemolytica
<b>Product Administration</b>	
Study Animals	Bovine
<b>Challenge Description</b>	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	July 17, 1996

124 4X49.21 Page 12 of 16

Study Type	Efficacy
Pertaining to	Bovine Parainfluenza Type 3 (PI <sub>3</sub> )
Study Purpose	Demonstration of efficacy against PI <sub>3</sub>
<b>Product Administration</b>	
Study Animals	Bovine
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	June 10, 2002

124 4X49.21 Page 13 of 16

Study Type	Efficacy
Pertaining to	Bovine Respiratory Syncytial Virus (BRSV)
Study Purpose	Demonstration of efficacy against BRSV
<b>Product Administration</b>	
<b>Study Animals</b>	Bovine
<b>Challenge Description</b>	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	June 14, 1994

124 4X49.21 Page 14 of 16

Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety under field conditions
<b>Product Administration</b>	
Study Animals	Bovine: pregnant cows and calves nursing pregnant cows provided
	the cows were vaccinated pre-breeding
<b>Challenge Description</b>	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
<b>USDA Approval Date</b>	December 6, 2005

124 4X49.21 Page 15 of 16

Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety under field conditions
<b>Product Administration</b>	One dose, subcutaneously
Study Animals	217 Bovine calves, 5 – 6.6 months of age
<b>Challenge Description</b>	Not applicable
Interval observed after	Not applicable
challenge	
Results	There were no local or systemic adverse reactions related to vaccination noted in any of the 217 calves during the 14 day post-vaccination observation period. The demographics of the calves is summarized as follows:    Months of Age
<b>USDA Approval Date</b>	October 22, 2007

124 4X49.21 Page 16 of 16